A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease

Abstract

	•Performed comprehensive genomics across liver biopsies of 396 MASLD patients and identified patients with increased, decreased and unchanged FGF21 expression.
	•Used genomic data from FGF21 transgenic, knock-out and animal MASLD models treated with synthetic FGF21 analogues to identify FGF21-mode-of-action and metabolic networks in human MASLD.
	•Given the significant heterogeneity in FGF21 expression, not all patients will benefit from FGF21-based therapies.

Keywords

fibroblast growth factor-21 / fibrosis / inflammation / metabolic dysfunction-associated steatotic liver disease / metabolism

References

[1] YounossiZM, GolabiP, PaikJM, Henry A, Van DongenC, HenryL. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4): 1335-1347.

[2] TangS, BorlakJ. Genomics of human NAFLD: lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures. Hepatology. 2024; 80(4): 901-915.

[3] ChuiZSW, ShenQ, XuA. Current status and future perspectives of FGF21 analogues in clinical trials. Trends Endocrinol Metab. 2024; 35(5): 371-384.

[4] HarrisonSA, RolphT, KnottM, Dubourg J. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol. 2024; 81(3): 562-576.

[5] Breher-EschS, SahiniN, TrinconeA, Wallstab C, BorlakJ. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease. BMC Med Genomics. 2018; 11(1): 111-117.

[6] LiH, FangQ, GaoF, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53(5): 934-940.

[7] KleinerDE, BruntEM, Van NattaM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313-1321.

[8] HughesCE, NibbsRJB. A guide to chemokines and their receptors. FEBS J. 2018; 285(16): 2944-2971.

[9] CameronMJKD. Cytokines, chemokines and their receptors. Madame Curie Bioscience Database [Internet]. Landes Bioscience; 2013.

[10] AizaraniN, Saviano A, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019; 572(7768): 199-204.

[11] NewmanAM, LiuCL, GreenMR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5): 453-457.

[12] ArteelGE, NabaA. The liver matrisome—looking beyond collagens. JHEP Rep. 2020; 2(4): 100115.

[13] NabaA, Clauser KR, WhittakerCA, CarrSA, TanabeKK, HynesRO. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer. 2014; 14: 518-518.

[14] ConoverWJ. Practical Nonparametric Statistics. 2nd ed. New York: Wiley, 1980.

[15] KelleyK. Confidence intervals for standardized effect sizes: theory, application, and implementation. J Stat Soft. 2007; 20(8): 1.

[16] WanX, LuX, XiaoY, et al. ATF4-and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Int. 2014; 2014: 807874.

[17] EricksonA, MoreauR. The regulation of FGF21 gene expression by metabolic factors and nutrients. Horm Mol Biol Clin Investig. 2016; 30(1). /j/hmbci.2017.30.issue–0016.

[18] ChenM, LiuY, YangY, et al. Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: implications in cancer immunotherapy. Genes Dis. 2021; 9(4): 981-999.

[19] NeillG, MassonGR. A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response. Front Mol Neurosci. 2023; 16: 1112253.

[20] ZhangY, FangB, DamleM, et al. HNF6 and rev-erbα integrate hepatic lipid metabolism by overlapping and distinct transcriptional mechanisms. Genes Dev. 2016; 30(14): 1636-1644.

[21] KumarR, MalK, RazaqMK, et al. Association of leptin with obesity and insulin resistance. Cureus. 2020; 12(12): e12178.

[22] Dagogo-JackS. Leptin and insulin sensitivity: endogenous signals of metabolic homeostasis. J Clin Endocrinol Metab. 2024; 109(5): e1402-e1403.

[23] EmanuelliB, Vienberg SG, SmythG, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest. 2014; 124(2): 515-527.

[24] PengH, ChiuT, LiangY, et al. PRAP1 is a novel lipid-binding protein that promotes lipid absorption by facilitating MTTP-mediated lipid transport. J Biol Chem. 2021; 296: 100052.

[25] ParkJ, LeeD, KimD. Redefining the role of AMPK in autophagy and the energy stress response. Nat Commun. 2023; 14(1): 2994.

[26] TsayA, WangJ. The role of PIK3R1 in metabolic function and insulin sensitivity. Int J Mol Sci. 2023; 24(16): 12665.

[27] WangRC, WeiY, AnZ, et al. Akt-mediated regulation of autophagy and tumorigenesis through beclin 1 phosphorylation. Science. 2012; 338(6109): 956-959.

[28] InokiK, LiY, ZhuT, WuJ, GuanK. TSC2 is phosphorylated and inhibited by akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9): 648-657.

[29] KimYC, GuanK. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015; 125(1): 25-32.

[30] LuoJ, ZhaoH, ChenL, Liu M. Multifaceted functions of RPS27a: an unconventional ribosomal protein. J Cell Physiol. 2023; 238(3): 485-497.

[31] ManSM, Kanneganti T. Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B. Autophagy. 2016; 12(12): 2504-2505.

[32] LiangQ, ZhongL, ZhangJ, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014; 63(12): 4064-4075.

[33] OzcanL, WongCCL, LiG, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab. 2012; 15(5): 739-751.

[34] StarkR, Pasquel F, TurcuA, et al. Phosphoenolpyruvate cycling via mitochondrial phosphoenolpyruvate carboxykinase links anaplerosis and mitochondrial GTP with insulin secretion. J Biol Chem. 2009; 284(39): 26578-26590.

[35] YeQ, LiuY, ZhangG, et al. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nat Commun. 2023; 14(1): 1402-1403.

[36] MutelE, Abdul-Wahed A, RamamonjisoaN, et al. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol. 2011; 54(3): 529-537.

[37] ChoiSY, HirataK, IshidaT, Quertermous T, CooperAD. Endothelial lipase: a new lipase on the block. J Lipid Res. 2002; 43(11): 1763-1769.

[38] CaoY, Pearman AT, ZimmermanGA, McIntyreTM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 2000; 97(21): 11280-11285.

[39] SatapatiS, SunnyNE, KucejovaB, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012; 53(6): 1080-1092.

[40] YangC, KoB, HensleyCT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014; 56(3): 414-424.

[41] ZhuL, LuuT, EmfingerCH, et al. CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet. Diabetes. 2018; 67(12): 2494-2506.

[42] ChiangJYL. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004; 40(3): 539-551.

[43] NieB, ParkHM, KazantzisM, et al. Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology. 2012; 56(4): 1300-1310.

[44] NimerN, Choucair I, WangZ, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021; 116: 154457.

[45] MaC, Kesarwala AH, EggertT, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016; 531(7593): 253-257.

[46] AmiotL, VuN, SamsonM. Biology of the immunomodulatory molecule HLA-G in human liver diseases. J Hepatol. 2015; 62(6): 1430-1437.

[47] LeeN, LlanoM, CarreteroM, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 1998; 95(9): 5199-5204.

[48] LiZ, JuX, SilveiraPA, et al. CD83: activation marker for antigen presenting cells and its therapeutic potential. Front Immunol. 2019; 10: 1312.

[49] GroscheL, Knippertz I, KönigC, et al. The CD83 molecule—an important immune checkpoint. Front Immunol. 2020; 11: 721.

[50] BarclayAN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014; 32: 25-50.

[51] YuY, HeJ, LiS, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol. 2016; 38: 144-152.

[52] FergussonJR, Fleming VM, KlenermanP. CD161-expressing human T cells. Front Immunol. 2011; 2: 36.

[53] NielsenCM, WhiteMJ, GoodierMR, Riley EM. Functional significance of CD57 expression on human NK cells and relevance to disease. Front Immunol. 2013; 4: 422.

[54] CheukS, Schlums H, Gallais Sérézal I, et al. CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin. Immunity. 2017; 46(2): 287-300.

[55] LoombaR, SanyalAJ, KowdleyKV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023; 389(11): 998-1008.

[56] MengX, Nikolic-Paterson DJ, LanHY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6): 325-338.

[57] RifkinDB, RifkinWJ, ZilberbergL. LTBPs in biology and medicine: lTBP diseases. Matrix Biol. 2018; 71–72: 90-99.

[58] NejjariM, Couvelard A, MosnierJF, et al. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol. 2001; 195(4): 473-481.

[59] RahmanSR, RoperJA, GroveJI, Aithal GP, PunKT, BennettAJ. Integrins as a drug target in liver fibrosis. Liver Int. 2022; 42(3): 507-521.

[60] MartinK, Pritchett J, LlewellynJ, et al. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun. 2016; 7: 12502.

[61] BostF, Diarra-Mehrpour M, MartinJP. Inter-alpha-trypsin inhibitor proteoglycan family–a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem. 1998; 252(3): 339-346.

[62] Schmidt-ArrasD, Rose-John S. Regulation of fibrotic processes in the liver by ADAM proteases. Cells. 2019; 8(10): 1226.

[63] SchwettmannL, Wehmeier M, JokovicD, et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol. 2008; 49(2): 243-250.

[64] TsutsuiK, ManabeR, YamadaT, et al. ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation. J Biol Chem. 2010; 285(7): 4870-4882.

[65] Ramos-DeSimoneN, Hahn-Dantona E, SipleyJ, NagaseH, FrenchDL, QuigleyJP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999; 274(19): 13066-13076.

[66] AlsharohH, Ismaiel A, LeucutaD, PopaS, Dumitrascu DL. Plasminogen activator inhibitor-1 levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2022; 31(2): 206-214.

[67] TripodiA, Fracanzani AL, PrimignaniM, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014; 61(1): 148-154.

[68] FarrellGC, TeohNC, McCuskeyRS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken). 2008; 291(6): 684-692.

[69] ChenL, GuT, LiB, et al. Delta-like ligand 4/DLL4 regulates the capillarization of liver sinusoidal endothelial cell and liver fibrogenesis. Biochim Biophys Acta Mol Cell Res. 2019; 1866(10): 1663-1675.

[70] PanR, XiangL, WangP, et al. Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of delta-like1. Hepatology. 2015; 61(5): 1708-1720.

[71] KliewerSA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019; 29(2): 246-253.

[72] ByunS, SeokS, KimY, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun. 2020; 11(1).

[73] ShenW, YangM, ChenH, et al. FGF21-mediated autophagy: remodeling the homeostasis in response to stress in liver diseases. Genes Dis. 2023; 11(3): 101027.

[74] LaplanteM, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013; 126(8): 1713-1719. Pt.

[75] ShimobayashiM, HallMN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014; 15(3): 155-162.

[76] WangL, HarrisTE, RothRA, Lawrence JCJ. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007; 282(27): 20036-20044.

[77] KimD, Sarbassov DD, AliSM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002; 110(2): 163-175.

[78] YangH, JiangX, LiB, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017; 552(7685): 368-373.

[79] TianC, HuangR, XiangM. SIRT1: harnessing multiple pathways to hinder NAFLD. Pharmacol Res. 2024; 203: 107155.

[80] YanB, MeiZ, TangY, et al. FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1. Cell Death Dis. 2023; 14(5): 311-319.

[81] CroonM, Szczepanowska K, PopovicM, et al. FGF21 modulates mitochondrial stress response in cardiomyocytes only under mild mitochondrial dysfunction. Sci Adv. 2022; 8(14): eabn7105.

[82] GongQ, HuZ, ZhangF, et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology. 2016; 64(2): 425-438.

[83] EmanuelliB, Vienberg SG, SmythG, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest. 2015; 125(1): 458.

[84] LiH, WuG, FangQ, et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun. 2018; 9(1): 272-279.

[85] MarkanKR, NaberMC, AmekaMK, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014; 63(12): 4057-4063.

[86] SpannRA, Morrison CD, den HartighLJ. The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol (Lausanne). 2022; 12: 802541.

[87] PotthoffMJ, Inagaki T, SatapatiS, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA. 2009; 106(26): 10853-10858.

[88] CoskunT, BinaHA, SchneiderMA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149(12): 6018-6027.

[89] ShenL, LiY, ZhaoH. Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases. Front Immunol. 2024; 15: 1390453.

[90] ZhaoY, LiuZ, YanT, et al. Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways. Acta Pharmacol Sin. 2024; 45(5): 988-1001.

[91] WangC, LiY, LiH, et al. Disruption of FGF signaling ameliorates inflammatory response in hepatic stellate cells. Front Cell Dev Biol. 2020; 8: 601.

[92] XieY, SuN, YangJ, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020; 5(1): 181.

[93] ZhaoX, HanD, ZhaoC, et al. New insights into the role of klotho in inflammation and fibrosis: molecular and cellular mechanisms. Front Immunol. 2024; 15: 1454142.

[94] SuzukiM, UeharaY, Motomura-MatsuzakaK, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008; 22(4): 1006-1014.

[95] Ocaña-GuzmanR, Vázquez-Bolaños L, Sada-OvalleI. Receptors that inhibit macrophage activation: mechanisms and signals of regulation and tolerance. J Immunol Res. 2018; 2018: 8695157.

[96] XuP, ZhangY, LiuY, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol. 2016; 290: 43-53.

[97] SahiniN, , Borlak J. Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. Transl Res. 2016; 177: 41-69.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.